Adverse Event Management

Brain Cancer

Breast Cancer

Disparities in Cancer Care

Drug Safety

Colorectal Cancer

Liver Cancer

Gastric Cancers

Gastrointestinal Cancer

Genetics

Kidney Carcinoma

Bladder Cancer

Prostate Cancer

Genitourinary Cancer

Endometrial Cancer

Cervical Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Leukemia

Multiple Myeloma

Lymphoma

Hematology

Immuno-Oncology

Lung Cancer

Myeloproliferative Neoplasms

Nurse Navigation

Pediatric Cancer

Practice Management

Prevention

Radiation Oncology

Sarcomas

Melanoma

Skin Cancer

Supportive Care

Survivorship

A phase 3 trial based out of India suggests that olanzapine may be useful in reducing chemotherapy-induced nausea and vomiting.

Olanzapine Significantly Reduces CINV in Patients Receiving MEC 

Incorporating frailty screenings into preexisting workflows may be an effective way to provide more holistic care to patients with head and neck cancer. 

Reimagining Frailty Screenings in Head and Neck Cancer

Investigators reflect on the Oncology Care Model and its implications.

Screening for Pain and Depression is Not Enough in Cancer Care

The median overall survival with niraparib, abiraterone acetate, and prednisone was 30.4 months vs 28.6 months with abiraterone acetate and prednisone alone.

Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC

News

Latest News

FDA News

Survivorship 

Contributors

Media

Podcasts

Videos

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Oncology Drug Crash Course

Webinars

Cancer Summary Slides

MPN Symptom Management

Subscribe

Print Subscription

eNewsletter

Partners

Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Frontline cadonilimab (AK104) and platinum-based chemotherapy improved progression-free survival in patients with recurrent or metastatic cervical cancer.

Cadonilimab/Chemotherapy Meets Primary End Point in Phase 3 AK104-303 Trial

Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com

The FDA has approved the non-covalent BTK inhibitor, pirtobrutinib, to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already undergone 2 lines of therapy.

FDA Grants Pirtobrutinib Accelerated Approval to Treat CLL/SLL in the Third Line

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma. 

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

The increasing use of biosimilars makes prophylaxis with growth factor more cost effective. 

Ellen Carr, RN, MSN, AOCN

Articles

Latest Conference Coverage